InvestorsHub Logo

GD

Followers 25
Posts 863
Boards Moderated 0
Alias Born 07/12/2002

GD

Re: Fosco1 post# 2478

Monday, 11/02/2020 11:13:20 AM

Monday, November 02, 2020 11:13:20 AM

Post# of 2794
I agree with your #2 view, what I mean is the efficacy is clearly
strong for approval, but data can not be analyzed by SAP plan, FDA
has to see the data with open mind to save patients' lives. FDA
has agreed this with OMER's TMA trial with only 28 patients compare
with literature.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ATNM News